Do generics offer significant savings to the UK National Health Service?

Current Medical Research and Opinion

Volumn 23, Issue 1, 2007, Pages 105-116

  Kanavos, Panos ^a  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

Author keywords

Cost sharing; Drug policy; Generic pharmaceuticals; Innovation; NHS; UK health policy

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIHYPERTENSIVE AGENT; CLAVULANIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FERROUS GLUCONATE; FERROUS ION; FERROUS SULFATE; GENERIC DRUG; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS LISINOPRIL; LISINOPRIL; MESALAZINE; METFORMIN; METHYLPHENIDATE; OMEPRAZOLE; PAROXETINE; SALBUTAMOL; SIMVASTATIN;

ARTICLE; DRUG BIOAVAILABILITY; DRUG CAPSULE; DRUG COST; DRUG MANUFACTURE; HEALTH SURVEY; HOSPITAL PHARMACY; HOSPITAL PURCHASING; NATIONAL HEALTH SERVICE; PRESCRIPTION; UNITED KINGDOM;

COST SAVINGS; COSTS AND COST ANALYSIS; DRUG COSTS; DRUGS, GENERIC; ECONOMICS, PHARMACEUTICAL; GREAT BRITAIN; HEALTH POLICY; HUMANS; NATIONAL HEALTH PROGRAMS; PRESCRIPTION FEES;

EID: 33846666462     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X159506     Document Type: Article

References (40)

1. Mossialos EA, Walley T, Mrazek M. Regulating pharmaceuticals in Europe: an overview (Chapter 1). In: Mossialos EA, Mrazek MF, Walley T, editors. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Buckingham: Open University Press; 2004
2. Kanavos P, Reinhardt U. Reference pricing for drugs: is it compatible with US health care? Health Aff (Milwood) 2003;22:16-30
3. Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000;51:149-62
4. Garattini S, Garattini L. Pharmaceutical prescriptions in four European countries. The Lancet 1993;342:1191-2
5. Kanavos P, Gemmill M. Pharmaceutical pricing and reimbursement in Europe. London: Informa Publishing; 2005
6. Mrazek MF, Mossialos EA. Regulating pharmaceutical prices in the European Union (Chapter 6). In: Mossialos EA, Mrazek MF, Walley T, editors. Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Buckingham: Open University Press; 2004
7. King DR, Kanavos P. Encouraging the use of generic medicines: implications for transition economies. Croatian Med J 2002;43:462-9
8. Kanavos P. International generic pharmaceutical policies. Richmond: PJB Publications Ltd; 2004
9. Soumerai SB. Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Aff (Millwood) 2004;23:135-46
10. Grabowski H, Vernon J. Longer patents for lower imitation barriers: the 1984 Drug Act. American Econ Rev Papers Proc 1986;76:195-8
11. PRODIGY. Practical, reliable, evidence-based guidance [online]. Available from http://www.prodigy.nhs.uk/Portal/Index.aspx [last accessed 13 April 2006]
12. Department of Health. Prescriptions dispensed in the community: statistics for 1993 to 2003, England [online]. Available from http://www.dh.gov.uk/PublicationsAndStatistics/Statistics/StatisticalWorkAreas/ StatisticalHealthCare/StatisticalHealthCareArticle/fs/en?CONTENT_ID= 4094064&chk=WatYL3 [last accessed 13 April 2006]
13. British Generic Manufacturers Association. Market: key facts [online]. Available from http://www.britishgenerics.co.uk/bgma.htm [last accessed 13 April 2006]
14. Department of Health. New long-term arrangements for reimbursement of generic medicines: scheme M. London: DoH; 2005
15. The Drug Tariff [online]. Available from http://www.drugtariff.com/ secure/generic_prices.htm [last accessed 13 April 2006]
16. Department of Health. Statutory instrument 2000 No. 1763: the Health Service Medicines (control of prices of specified generic medicines) Regulations 2000, Crown Copyright 2000; http://www.opsi.gov.uk/si/si2000/20001763.htm [accessed 16 September 2005]
17. Department of Health. Statutory instrument 2001 No. 3798: the Health Service Medicines (information on the prices of specified generic medicines) Regulations 2001 [online]. Available from http://www.opsi.gov.uk/si/si2001/ 20013798.htm [last accessed 13 April 2006]
18. Grabowski H, Vernon J. Brand loyalty, entry, and price competition in pharmaceuticals after the 1984 Drug Act. J Law Econs 1992;35:331-51
19. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ Man Strat 1997;6:75-90
20. United States Congressional Budget Office (CBO). How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry. Washington (DC): CBO; 1998 [online]. Available from: http://www.cbo.gov/showdoc.cfm?index=655&sequence=0.2001 [last accessed 13 April 2006]
21. Caves R, Whinston M, Hurwitz M. Patent expiration, entry, and competition in the US pharmaceutical industry: an exploratory analysis. Brookings papers on Economic Activity: Microeconomics 1991;1-48
22. Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Policy 2004;68:47-54
23. Intercontinental Medical Statistics (IMS). Generics: moving up the value chain to higher priced products [online]. Available from http://open.imshealth. com/webshop2/IMSinclude/i_article_20040518b.asp [last accessed 13 April 2006]
24. Mrazek MF, Mossialos E. Increasing demand while decreasing costs of generic medicines. The Lancet 2000;356:1784-5
25. UK Department of Health, NHS Executive. Generic drug prices and proposals to set maximum prices for generic medicines. Leeds: NHS Executive; 2000
26. Oxford Economic Research Associates. Fundamental review of the generic drugs market. Report prepared by OXERA on behalf of the UK Department of Health; 2001 July. Available from: http://www.doh.gov.uk/generics/ oxera_report_no_frames.htm
27. Department of Health. Options for the future supply and reimbursement of generic medicines for the NHS: a discussion paper. London: Department of Health; 2001
28. Department of Health. Contractual framework for community pharmacy. http://www.dh.gov.uk/PolicyAndGuidance/MedicinesPharmacyAndIndustry/ CommunityPharmacyContractualFramework/fs/en [accessed 29 July 2005]
29. Office of Fair Trading. The control of entry regulations and retail pharmacy services in the UK. Crown Copyright 2003 [online]. Available from http://www.oft.gov.uk/NR/rdonlyres/BABF839A-3088-4EBB-B3A9-00D955719EE0/0/ oft609.pdf [last accessed 13 April 2006]
30. The New Frontiers Business Development Seminar 2006. New frontiers: your fast-track to the UK pharmacy market [online]. Available from www.buyusa.gov/nevada/uknewfrontiers.pdf [last accessed 13 April 2006]
31. Intercontinental Medical Statistics (IMS), Acts 2002, IMS Health Quality Assurance, 2002
32. Clement W, Tuma M, Walter E. The European pharmaceutical wholesale industry: structure, trends and socio-economic importance. Commissioned by the European Association of pharmaceutical full-line wholesalers (GIRP) [online]. Available from http://girp.org/newstudy/ StudyTheEuropeanPharmaceuticalWholesaleIndustry.pdf [last accessed 13 April 2006]. Vienna: Institute for Pharmacoeconomic Research; November 2005
33. British Generic Manufacturers Association (BGMA). Members list [online]. Available from http://www.britishgenerics.co.uk/bgma.htm [last accessed 13 April 2006]
34. Commission of the European Communities. Second round table: completing the single pharmaceutical market, Frankfurt, 8 December 1997, contribution of DGIII- Directorate General for Industry. http://ec.europa.eu/enterprise/ pharmaceuticals/smarket/pdf/pd212.pdf [accessed 17 July 2006]
35. European Generic Medicines Association. Encouraging greater use of generic medicines in the European healthcare market. Report by the Health Economics Committee of the European Generic Medicines Association. 15 October 1998. http://ec.europa.eu/enterprise/pharmaceuticals/smarket/pdf/ega.pdf [accessed 17 July 2006]
36. Kanavos P, Costa-Font J. Pharmaceutical parallel trade in Europe: stakeholder and competition effects. Econ Policy 2005;45:752-98
37. United States Department of Commerce, International Trade Administration. Pharmaceutical price controls in OECD countries: implications for US consumers, pricing, research and development and innovation. Washington (DC): US Department of Commerce, International Trade Administration; December 2004
38. Deutsche Bank. European generics: plenty in the pipeline. Equity Research, Frankfurt; 24 April 2002
39. LSE Health. Impact of generic drug policies on the availability and use of pharmaceutical products. London: report for the World Health Organization (mimeo); February 2000
40. Department of Health. Prescription cost analysis: sources, glossary of terms and codes used and availability of published data. http://www.dh.gov.uk/ assetRoot/04/10/76/29/04107629.pdf [accessed 24 September 2005]